Neovii Advances Type 1 Diabetes Program with Phase 2 Study

Neovii Pharmaceuticals AG, a biopharmaceutical company specializing in antibody-based therapies, is advancing its Type 1 Diabetes (T1D) program with a pivotal Phase 2 study in the US and EU. Supported by the FDA's Fast Track designation, this study aims to prevent declining C-peptide production with anti-T-lymphocyte globulin (ATLG).

Patients in the European GIRO study are already receiving treatment, and the upcoming interim analysis will be crucial for the study’s progression. This marks a significant expansion for Neovii as it moves beyond transplantation in immune-mediated diseases.

Salvatore "Salvo" Alesci, M.D., Ph.D., joins as Chief Medical Officer to lead clinical development. His expertise will guide Neovii’s broader strategy in immune-mediated diseases as they expand research in this area.